ArticleJHEP reports : innovation in hepatology2025
Prognostic value of radiological and pathological complete response following immune-based conversion therapy in patients with unresectable hepatocellular carcinoma (GUIDANCE004).
Article in JHEP reports : innovation in hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06405321 (Conversion or Neoadjuvant Therapy in Hepatocellular Carcinoma), which is not on this map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Conversion or Neoadjuvant Therapy in Hepatocellular Carcinoma: A Multicenter Retrospective Study in Guangxi, China (GUIDANCE)
Who cites it
8 citing papers in PubMed.
- Prognostic Usefulness of Clinical Complete Response after PD-1 Inhibitor-Based Combination Therapy for Unresectable Hepatocellular Carcinoma (GUIDANCE006).Liver cancer · 2026Article
- Article
- Immune Checkpoint Inhibitor Rechallenge in Unresectable Hepatocellular Carcinoma: A Multicenter Efficacy and Safety Study.Liver cancer · 2026Article
- Neoadjuvant transarterial chemoembolization with tyrosine kinase and immune checkpoint inhibitors improves survival from resectable hepatocellular carcinoma in a multicenter, retrospective study (GUIDANCE002).Communications medicine · 2026Article
- When Resectability Emerges After Systemic Therapy in Hepatocellular Carcinoma: A Proposed Response-Guided Consolidation Framework.Journal of hepatocellular carcinoma · 2026Review
- Stage-Dependent Efficacy of TACE Combined with Tyrosine Kinase and Immune Checkpoint Inhibitors as Conversion Therapy for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study.Journal of hepatocellular carcinoma · 2026Article
- The SAGES scoring model leads to personalized treatment via the combination of TACE, TKIs and ICIs for unresectable hepatocellular carcinoma.Frontiers in immunology · 2026Article
- Optimal timing of surgery after conversion therapy for initially unresectable hepatocellular carcinoma: a multicenter study integrating major pathological response and treatment duration.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
44 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & aims: It is unclear whether radiological complete response (rCR) and pathological complete response (pCR) after immune-based conversion therapy are associated with each other and with the prognosis of patients with initially unresectable hepatocellular carcinoma (uHCC). Methods: Data were retrospectively analyzed from 1,262 patients with uHCC who received immune-based conversion therapy at 22 medical centers across China between 2019 and 2023. Survival was compared among patients showing different responses through conventional analysis of all patients, conventional analysis of propensity score-matched subgroups, and landmark analyses at 5 and 7 months after treatment. Results: Conversion therapy led to tumor downstaging in 343 patients (27.2%) and upstaging in 91 (7.2%) based on modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria. The 254 patients who achieved rCR showed significantly better overall survival at 3 years than the 1,008 who did not (79.4% Conclusions: Both rCR and pCR may be reliable indicators of prognosis after immune-based conversion therapy in patients with uHCC. These metrics and their predictors may be useful for selecting which patients can benefit from conversion therapy. Impact and implications: It is unclear whether radiological and pathological complete responses after immune-based conversion therapy are associated with each other and with the prognosis of patients with initially unresectable hepatocellular carcinoma. This large-scale retrospective study demonstrates a strong correlation between radiographic and pathologic complete responses, both of which are associated with significantly improved survival outcomes. These findings provide valuable clinical insights, indicating that radiological and pathological complete responses may serve as reliable prognostic indicators following immune-based conversion therapy in this patient population. Furthermore, these response metrics could be used to identify patients most likely to benefit from such therapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.